Vertex Pharmaceuticals (VRTX) saw a
decline greater than the overall market.
Gateway Investment Advisers and Dynamic Advisor Solutions have downsized their positions in the company. It's Q2 2024 results depict
growth navigation challenges. Amidst M&A trends, Vertex showed limited upside leading to a
downgrade. Analysts from
Raymond James and
Cantor Fitzgerald reiterated and extended their
positive ratings, respectively. The company’s attention towards
cystic fibrosis and non-addictive
pain drug is noteworthy. Q2 results revealed a revenue miss which along with an
insider sale by top executives led to a stock dip, despite the
increased 2024 outlook. There is
high interest among investors and hedge funds. Analyst recommendations and Jim Cramer stand positive. The performances of their cystic fibrosis treatments led to an increase in annual revenue forecast.
FDA accepted NDA for Suzetrigine boosting their stock performance. Lastly, Vertex's bet on a
$4.9 billion kidney disease treatment sparks interest.
Vertex Pharmaceuticals VRTX News Analytics from Tue, 12 Mar 2024 07:00:00 GMT to Sat, 12 Oct 2024 16:12:07 GMT -
Rating -4
- Innovation 6
- Information 4
- Rumor -6
